📰 Exalenz Bioscience News
Exalenz Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Exalenz Bioscience. Real-time updates on events, politics, business and more.
May 28, 2024
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 ________________________ Dear NeuroSense Therapeutics Ltd....
December 13, 2023
/PRNewswire/ - Further to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) shareholders...
December 13, 2023
SYMETRYX RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER SYMETRYX RECOMMENDS VOTING FOR THEIR QUALIFIED INDEPENDENT BOARD NOMINEES TIME IS SHORT - THE VOTE DEADLINE IS 11:59 pm EST THURSDAY...
June 21, 2023
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 26, 2023 ... | June 21, 2023
January 6, 2023
Join us on Thursday, February 9 as we realign and power up sales for the unique landscape presented by 2023.
May 9, 2022
The global norovirus diagnostics market was valued at US$ 47.6 Mn in 2020, and is expected to exhibit a CAGR of around 8.4% between 2021-2031.
October 20, 2021
/PRNewswire/ -- As per Persistence Market Researchs latest industry analysis, the global norovirus diagnostics market was valued at US$ 47.6 Mn in 2020, and...
October 20, 2021
/PRNewswire/ -- As per Persistence Market Researchs latest industry analysis, the global norovirus diagnostics market was valued at US$ 47.6 Mn in 2020, and...
May 7, 2021
Message : Required fields CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 million, up 49% year-over-year Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year Diagnostics segment net revenues decreased 9% year-over-year to $31.9 million, u...